Project ALS

Star Mountain Capital Adds Former Dallas Fed CEO, Goldman Sachs Vice Chairman, Robert Kaplan, as Senior Advisor

Retrieved on: 
Tuesday, February 13, 2024
Asset Management, Professional Services, Finance, Federal Reserve Bank, Advisory board, Senior, Baker Institute, Draper Richards Kaplan Foundation, Professor, Project, Friends, Star, Ford Foundation, Advisory Council, State Street Corporation, Senior advisor, Trustee, Harvard University endowment, Interim, Starr Mountain, Investment banking, Goldman Sachs, Harvard Medical School, Project ALS, Harvard Business School, Book, Management

Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.

Key Points: 
  • Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240213968210/en/
    Robert S. Kaplan, Star Mountain Capital Senior Advisor (Photo: Business Wire)
    Robert Kaplan has over 40 years of investment management, business management, monetary policy, investment banking, and leadership experience.
  • His previous positions include CEO and President of the Federal Reserve Bank of Dallas, Vice Chairman of Investment Banking and Investment Management Divisions of Goldman Sachs, and Professor and Senior Associate Dean of Harvard Business School.
  • “We are honored to have Rob join Star Mountain as an aligned Senior Advisor bringing extensive investment, strategic leadership, business management and governance experience,” said Brett Hickey , Star Mountain Capital Founder & CEO.

ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors

Retrieved on: 
Thursday, November 2, 2023
FDA, US, Merck & Co., Economics, Dickinson College, Merck, CNS, MBA, Project ALS, US Market Access Center, Prosetín, Wharton School of the University of Pennsylvania, Growth, ALS, Marketing, University, MAP4K, Columbia University, Pharmaceutical industry

In addition, ProJenX announced the appointment of Rick Hartz to its board of directors.

Key Points: 
  • In addition, ProJenX announced the appointment of Rick Hartz to its board of directors.
  • At Merck, he leads a global commercial team responsible for cardiovascular, respiratory, metabolic, infectious disease, hospital/specialty, immunology, and neuroscience.
  • Previous positions at Merck include SVP for Global Oncology Partnerships, SVP US Managed Markets and Chief Marketing Officer, US Market.
  • "I am excited to join the ProJenX Board and contribute to its mission to advance promising therapies for ALS and other neurodegenerative diseases," added Mr. Hartz.

Ben Stiller, Christine Taylor, and Julianna Margulies Commemorate 25 Years of Project ALS Research Progress

Retrieved on: 
Wednesday, October 18, 2023
Lincoln Center, Family, Parkinson's disease, Neurodegenerative disease, Project, Research, Brain cell, Project ALS, Multimedia, Huntington's disease, Jazz, ALS, Clinical trial, Partnership, Music, Alzheimer's disease, PizzaExpress Jazz Club, Movement, Map, Diagnosis, Tomorrow, Nightclub, Medicinal plants, Aluminium

NEW YORK, Oct. 18, 2023 /PRNewswire/ -- Project ALS –non-profit 501(c)3 leader in the pursuit of treatments and a cure for the neurodegenerative disease ALS– in partnership with hosts Ben Stiller and Christine Taylor, celebrates 25 years of dedicated research and interindustry support at "Tomorrow is Tonight Gala."

Key Points: 
  • Ben Stiller and Christine Taylor, a member of the Project ALS board of directors, are the faces of the entertainment industry's unwavering support of the Project ALS mission.
  • When Project ALS founder and up-and-coming theater producer, Jenifer Estess, received an ALS diagnosis in 1997, her dear friends, Ben Stiller, Julianna Margulies, and an extended troupe throughout the entertainment community bonded to bolster fundraising efforts.
  • "I'm looking forward to celebrating 25 years of progress with the Estess sisters and the extended Project ALS family.
  • Project ALS is a not-for-profit, 501(c)3 whose mission is to identify and fund ALS and related research toward effective treatments and a cure.

ProJenX Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, March 30, 2023
Columbia University, SAB, Columbia University Irving Medical Center, Research and development, Drug development, University Medical Center Utrecht, MAP4K, Harvard University, Coronavirus Scientific Advisory Board, Neuroscience, Research, Doctor of Philosophy, Eleanor, UC, UMC, University of California, Irvine, Drug discovery, Neurology, Knowledge, Entrepreneurship, Project ALS, ALS, Disease, MAP, Pharmaceutical industry, MD

NEW YORK, March 30, 2023 /PRNewswire/ -- ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • NEW YORK, March 30, 2023 /PRNewswire/ -- ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB).
  • I am excited by the research behind prosetin and look forward to working with ProJenX to elucidate and intervene in the key cellular pathways involved in ALS and neurodegeneration."
  • Erin Fleming, Co-Founder and Vice President of Research & Development at ProJenX, said, "We are honored to convene a world-class Scientific Advisory Board, who represent peerless experience and knowledge across ALS drug development, data-driven clinical trial design, and the MAP kinase pathway in neurodegeneration.
  • With our advisors' leadership, ProJenX is poised to translate decades of scientific discovery to people with ALS—beginning with prosetin."

ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO

Retrieved on: 
Wednesday, May 18, 2022
Laboratory, Eli Lilly and Company, NEW, ER, Endoplasmic reticulum, Leadership, Therapy, Forest Laboratories, Amyotrophic lateral sclerosis, Novartis, Research, Johnson & Johnson, FDA, Neurological disorder, Neurodegeneration, Industry, Abel, University of Chicago Booth School of Business, University, Heart failure, Pathology, Chronic pain, Project ALS, Heart, Sale, Drug development, Operation, Entrepreneurship, CFO, Columbia University, Business, ALS, Interim, CEO, Pharmaceutical industry, Company, Indiana University

Abel, who has more than 20 years of senior management and financial experience in the life sciences industry, has an extensive background in building and leading biopharmaceutical companies.

Key Points: 
  • Abel, who has more than 20 years of senior management and financial experience in the life sciences industry, has an extensive background in building and leading biopharmaceutical companies.
  • Prior to joining ProJenX, Abel was CEO of SiteOne Therapeutics Inc., where he led a team developing new treatments for acute and chronic pain.
  • Before this, he was CEO of Corthera Inc. through its sale to Novartis with a focus on a new treatment for heart failure.
  • "We are extremely pleased that Stan has joined us and accepted the role of ProJenX CEO," said Eric Heil, Interim CEO and Chairman of ProJenX.

ProJenX launches to advance novel, targeted therapies for ALS and other brain diseases

Retrieved on: 
Wednesday, February 16, 2022
Columbia University, Chemistry, Amyotrophic lateral sclerosis, Pathology, Columbia, Patient, Family, MEC, Entrepreneurship, Center, Friends, Core, Endoplasmic reticulum stress in beta cells, MAP4, Precision medicine, Directorate of Research and Civil Affairs, Disease, Prosetín, Synthetic biology, ALS, Project ALS, Neurological disorder, Lipidomics, Artificial intelligence, Regenerative medicine, Global Medical Excellence Cluster, Therapy, Project, Multimedia, Drug discovery, Translation, Cell biology, Biology, Drug development, LLC, Heart, Pharmaceutical industry, Research, DRS

A $5.1M seed financing was led by Medical Excellence Capital, which created ProJenX in collaboration with Project ALS, a leading nonprofit organization committed to ALS research, and with renowned researchers at Columbia University.

Key Points: 
  • A $5.1M seed financing was led by Medical Excellence Capital, which created ProJenX in collaboration with Project ALS, a leading nonprofit organization committed to ALS research, and with renowned researchers at Columbia University.
  • ProJenX will build on the efforts initiated by Columbia and Project ALS to advance prosetin through ALS clinical trials with urgency, humanity, and scientific rigor.
  • The company is named in honor of Project ALS founder Jenifer Estess, whowas diagnosed with ALS at age 35.
  • ProJenX is a clinical stage biotechnology company with novel, brain-penetrant, targeted therapies to address untreatable brain diseases, with an initial focus on ALS.

Project ALS Announces Research Advisory Board 2.0

Retrieved on: 
Wednesday, October 20, 2021
ALS, Core, Volunteering, Salk Institute for Biological Studies, Motor neuron, Technology, Project, Hospital, James Wilson, Child, Alsys, Doctor of Philosophy, Harvard Medical School, Drug development, Alzheimer's disease, University of Pennsylvania, Multimedia, MIT, RAB, Disease, Regeneron Pharmaceuticals, Research, Neurodegeneration, Therapy, Leadership, Boston Children's Hospital, Patient, University, Industry, Jonas Salk, Columbia University, Parkinson's disease, Project ALS, Huntington's disease, National Core for Neuroethics, University of Massachusetts, Movement, Pharmaceutical industry

NEW YORK, Oct. 20, 2021 /PRNewswire/ --Project ALS, a non-profit 501(c)3 leader in the pursuit of treatments and a cure for the neurodegenerative disease ALS, has announced its research advisory board (RAB).

Key Points: 
  • NEW YORK, Oct. 20, 2021 /PRNewswire/ --Project ALS, a non-profit 501(c)3 leader in the pursuit of treatments and a cure for the neurodegenerative disease ALS, has announced its research advisory board (RAB).
  • "Project ALS is excited to work with this RABthe most distinguished group of experts we've assembled to date," said Valerie Estess, Project ALS co-founder and director of research.
  • The Project ALS RAB is charged with assessing research progress at theProject ALS Therapeutics Core at Columbia(the Core).
  • The Project ALS Therapeutics Core at Columbia (the Core)is the centerpiece of current Project ALS research efforts.

Project ALS Granted FDA Orphan Drug Designation for Prosetin for the Treatment of Amyotrophic Lateral Sclerosis

Retrieved on: 
Friday, September 4, 2020
Neurological disorders, Neurodegenerative disorders, Nervous system, Project ALS, Amyotrophic lateral sclerosis, Orphan drug

NEW YORK, Sept. 4, 2020 /PRNewswire/ --Project ALS, a non-profit 501(c)3 organization that funds research toward the first meaningful treatments for amyotrophic lateral sclerosis (ALS), announced today that the Food and Drug Administration (FDA) has granted orphan drug designation to prosetin for the treatment ofALS.

Key Points: 
  • NEW YORK, Sept. 4, 2020 /PRNewswire/ --Project ALS, a non-profit 501(c)3 organization that funds research toward the first meaningful treatments for amyotrophic lateral sclerosis (ALS), announced today that the Food and Drug Administration (FDA) has granted orphan drug designation to prosetin for the treatment ofALS.
  • Prosetin is an oral, brain penetrant MAP4 kinase inhibitor developed by scientists at Columbia University for the treatment of ALS.
  • Project ALS funded prosetin's preclinical development and is sponsoring its translational and potential clinical development.
  • "Receiving orphan drug designation is an important milestone," said Meredith Estess, president and co-founder of Project ALS.

Medidata Institute and Project ALS Launch Partnership to Accelerate New Treatment Strategies

Retrieved on: 
Thursday, February 27, 2020
Technology, Medical devices, Other Technology, Clinical trials, Software, Biotechnology, Health, Pharmaceutical, Data management, Clinical data management, Medidata Solutions, Companies, Health, Amyotrophic lateral sclerosis, Project ALS, Dassault Group, Acorn Computers, Medidata, Medidata Institute and Acorn AI, Project ALS

Medidata, a Dassault Systmes company, and the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced the launch of a research partnership between the Medidata Institute and Project ALS .

Key Points: 
  • Medidata, a Dassault Systmes company, and the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced the launch of a research partnership between the Medidata Institute and Project ALS .
  • [ Video of Glen de Vries and Sheila Diamond of the Medidata Institute discuss the partnership.]
  • The partnership with Medidata will bring both talent and technology resources crucial to our efforts, said Meredith Estess, president, Project ALS.
  • Medidata, Medidata Rave, and Acorn AI are registered trademarks of Medidata Solutions, Inc., a wholly-owned subsidiary of Dassault Systmes.

BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development

Retrieved on: 
Friday, September 27, 2019
Neurological disorders, Nervous system, Neurodegenerative disorders, ALS Therapy Development Institute, Amyotrophic lateral sclerosis, ALS Association, Project ALS, Draft:BrainStorm Cell Therapeutics

This document outlines ALS drug development guidelines and potential opportunities to advance novel ALS therapies through innovative clinical trial design and validated clinical outcome measures.

Key Points: 
  • This document outlines ALS drug development guidelines and potential opportunities to advance novel ALS therapies through innovative clinical trial design and validated clinical outcome measures.
  • Members of the ALS Community included: ALS Association , ALS One , Compassionate Care ALS , NoMoreExcuses, ALS Therapy Development Institute , Paralyzed Veterans of America , IamALS , and Project ALS .
  • Chaim Lebovits, President and CEO of BrainStorm stated, The updated guidelines recognize the serious and life-threatening nature of ALS and enormous unmet need.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.